araag2/HINT huggingface dataset:
Clinical trial NCT02452190 (phase 3, status: completed)
Conditions: asthma
ICD codes: J45.998, J82.83, J45.909, J45.991, J45.20, J45.30, J45.40
Drugs: reslizumab, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Written informed consent is obtained.

          -  The participant is male or female, 12 years of age and older, with a diagnosis of
             asthma.

          -  The participant has Forced Expiratory Volume in 1 Second (FEV1) reversibility
             according to standard American Thoracic Society (ATS) or European Respiratory Society
             (ERS) protocol.

          -  The participant has required an inhaled corticosteroid.

          -  The participant has required an additional asthma controller medication besides
             inhaled corticosteroids.

          -  The participant has a history of asthma exacerbation.

          -  The participant must be willing and able to comply with study restrictions, perform
             requisite procedures and remain at the clinic for the required duration during the
             study period, and be willing to return to the clinic for the follow-up evaluation as
             specified in this protocol.

               -  Additional criteria may apply, please contact the investigator for more
                  information

        Exclusion Criteria:

          -  The participant has any clinically significant, uncontrolled medical condition
             (treated or untreated) that would interfere with the study schedule or procedures,
             interpretation of efficacy results, or compromise the patient's safety.

          -  The participant has another confounding underlying lung disorder

          -  The participant has a known hypereosinophilic syndrome.

          -  The participant has a diagnosis of malignancy within 5 years of the screening visit,
             except for treated and cured non-melanoma skin cancers.

          -  The participant is a pregnant or lactating woman, or intends to become pregnant during
             the study. Any woman becoming pregnant during the study will be withdrawn from the
             study.

          -  The participant is a current smoker or has a smoking history.

          -  The participated in a clinical trial within 30 days or 5 half-lives of the
             investigational drug before screening, whichever is longer.

          -  The participant was previously exposed to reslizumab.

          -  The participant has a history of an immunodeficiency disorder including human
             immunodeficiency virus (HIV).

          -  The participant has current or suspected drug and alcohol abuse.

          -  The participant has an active helminthic parasitic infection or was treated for one
             within 6 months of screening.

          -  The participant has a history of allergic reaction or hypersensitivity to any
             component of the study drug.

               -  Additional criteria may apply, please contact the investigator for more
                  information
Clinical trial NCT02453256 (phase 3, status: completed)
Conditions: systemic sclerosis
ICD codes: M34.0, M34.89, M34.9, M34.82, M34.83, M34.81, M34.2
Drugs: placebo, tocilizumab
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of SSc according to American College of Rheumatology (ACR) and European
             League Against Rheumatism (EULAR) criteria, meeting criteria for active disease and
             with total disease duration of less than or equal to (</=) 60 months

          -  mRSS of 10-35 units, inclusive

          -  Agreement to remain abstinent or use an effective contraceptive method among males and
             females with childbearing potential

        Exclusion Criteria:

          -  Pregnant or lactating females

          -  Major surgery within 8 weeks prior to screening

          -  Scleroderma limited to the face or areas distal to the elbows or knees

          -  Rheumatic autoimmune disease other than SSc

          -  Immunization with a live or attenuated vaccine within 4 weeks prior to Baseline

          -  Known hypersensitivity to human, humanized, or murine monoclonal antibodies

          -  Moderately severe nervous system, renal, endocrine, pulmonary, cardiovascular, or
             gastrointestinal (GI) disease not related to SSc, including diverticulitis or
             ulcerative lower GI disorders, or myocardial infarction (MI) within 6 months prior to
             screening

          -  Active or significant history of infection, including treatment with intravenous (IV)
             antibiotics within 4 weeks or oral antibiotics within 2 weeks prior to screening

          -  Significant history of tuberculosis (TB)

          -  Primary or secondary immunodeficiency

          -  Malignant disease, with the exception of excised/cured local basal or squamous cell
             carcinoma of the skin or carcinoma in situ of the uterine cervix

          -  History of drug or alcohol abuse
Clinical trial NCT02453282 (phase 3, status: active, not recruiting)
Conditions: non-small-cell lung carcinoma nsclc
ICD codes: D02.20, D02.21, D02.22
Drugs: paclitaxel + carboplatin, gemcitabine + cisplatin, gemcitabine + carboplatin, pemetrexed + cisplatin, pemetrexed + carboplatin
SMILES: [H][N]([H])([H])[Pt]1(OC(=O)C2(CCC2)C(=O)O1)[N]([H])([H])[H], [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H], [H][N]([H])([H])[Pt]1(OC(=O)C2(CCC2)C(=O)O1)[N]([H])([H])[H], [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H], [H][N]([H])([H])[Pt]1(OC(=O)C2(CCC2)C(=O)O1)[N]([H])([H])[H]
Eligibility criteria:

        Inclusion Criteria:

        For inclusion in the study, patients should fulfill the following criteria:

          -  Aged at least 18 years

          -  Documented evidence of Stage IV NSCLC

          -  No sensitizing EGFR mutation or ALK rearrangement

          -  No prior chemotherapy or any other systemic therapy for recurrent/metastatic NSCLC

          -  World Health Organization (WHO) Performance Status of 0 or 1

        Exclusion Criteria:

        Patients should not enter the study if any of the following exclusion criteria are
        fulfilled:

          1. Mixed small-cell lung cancer and NSCLC histology, sarcomatoid variant

          2. Brain metastases or spinal cord compression unless asymptomatic, treated and stable
             (not requiring steroids)

          3. Prior exposure to Immunomodulatory therapy (IMT), including, but not limited to, other
             anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), anti-programmed cell death1
             (PD-1), anti-programmed cell death ligand 1 (PD-L1), or anti PD-L2 antibodies,
             excluding therapeutic anticancer vaccines

          4. Active or prior documented autoimmune or inflammatory disorders (including
             inflammatory bowel disease [eg, colitis or Crohn's disease]
Clinical trial NCT02453386 (phase 3, status: terminated)
Conditions: idiopathic parkinson's disease
ICD codes: G20
Drugs: tozadenant, placebo
SMILES: COC1=C2N=C(NC(=O)N3CCC(C)(O)CC3)SC2=C(C=C1)N1CCOCC1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    new safety information
  
Eligibility criteria:

        Inclusion Criteria:

          -  Patient understands study requirements and has given his/her written informed consent
             on an Institutional Review Board (IRB) or Independent Ethics Committee (IEC) approved
             consent form.

          -  Parkinson's disease diagnosis consistent with UK Parkinson's Disease Society Brain
             Bank Diagnostic criteria

          -  Minimum of 3 years since diagnosis.

          -  Meet Hoehn and Yahr PD stage

          -  Good response to levodopa

          -  Stable regimen of anti-PD medications

          -  Patients must have been taking a levodopa-containing anti-PD medication continuously
             for at least the previous 12 months

          -  Patient has documented a minimum amount of Off time.

          -  If of childbearing potential (male and female) must use an acceptable method of
             contraception

        Exclusion Criteria:

          -  Previous tozadenant study participation

          -  Current or recent participation in another study.

          -  Secondary or atypical parkinsonism

          -  Neurosurgical intervention for PD

          -  Patient is taking apomorphine, budipine, istradefylline, tolcapone, or DUOPA™/Duodopa®

          -  Treatment with excluded medications

          -  Untreated or uncontrolled hyperthyroidism or hypothyroidism

          -  Clinically significant out-of-range laboratory

          -  MMSE out of range

          -  Current episode of major depression (stable treatment for depression is permitted).

          -  Recent suicide attempt or suicidal ideation type 4 or type 5 of the Columbia-Suicide
             Severity Rating Scale (C-SSRS)

          -  Women lactating or pregnant

          -  Hypersensitivity to any components of tozadenant or excipients

          -  Abnormal findings on the physical or neurological examination, or medical history that
             would make the patient unsuitable for the study

          -  History of hepatitis or cholangitis
Clinical trial NCT02455362 (phase 3, status: withdrawn)
Conditions: chronic obstructive pulmonary disease, dyspnea
ICD codes: J44.9, J44.1, J44.0, R06.00, R06.09
Drugs: morphine sulfate, placebo
SMILES: [H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])C=C[C@@H]2O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    'recruitment not possible given changes to trial criteria
  
Eligibility criteria:

        Inclusion Criteria:

          -  18 years of age or older.

          -  Physician diagnosed COPD confirmed by spirometry, defined as a prior
             post-bronchodilator FEV1/FVC < 0.7 in accordance with the GOLD 2014 criteria

          -  On stable medications relating to the optimal treatment of COPD or its symptomatic
             management over the prior week except routine "as needed" medications.

          -  Breathlessness of a level two (2) or higher on the modified Medical Research Council
             (mMRC) dyspnoea scale

          -  English speaking with sufficient reading and writing ability to complete the study
             questionnaires

          -  Assessed as competent (using SLUMS score of 27 for high school, and 25 for less than
             high school)

          -  Able and willing to give written informed consent

        Exclusion Criteria:

          -  On regularly prescribed opioid medications, including codeine preparations at or above
             8mg oral morphine equivalent daily in the previous seven (7) days.

          -  History of adverse reactions to any of the study medications or constituents in the
             placebo;

          -  Australian-modified Karnofsky performance score (AKPS) less than 50 at the beginning
             of the study.

          -  Respiratory or cardiac event in the previous one week (excluding upper respiratory
             tract infections). Illness must have resolved completely prior to baseline evaluation,
             as judged by the person's treating physician.

          -  Evidence of respiratory depression with resting respiratory rate <8/min.

          -  Documented central hypoventilation syndrome.

          -  Chronic alcoholism, or previous or recent history of substance misuse.

          -  Uncontrolled nausea, vomiting or evidence of a gastrointestinal tract obstruction.

          -  Renal dysfunction with creatinine clearance calculated (MDRD) less than 20 mls/minute.

          -  Evidence of severe hepatic impairment defined as transaminases or bilirubin >4x normal
             (Excluding Gilbert's syndrome)

          -  Pregnant or breastfeeding.
Clinical trial NCT02456740 (phase 3, status: completed)
Conditions: migraine
ICD codes: G43.B1, G43.D1, G43.B0, G43.D0, G43.A1, G43.411, G43.419
Drugs: erenumab, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  History of migraine (with or without aura) for ≥ 12 months prior to screening
             according to the International Headache Society (IHS) International Classification of
             Headache Disorders (ICHD-3) classification

          -  Migraine frequency: ≥ 4 and < 15 migraine days per month on average across the 3
             months prior to screening and during baseline

          -  Headache frequency: < 15 headache days per month on average across the 3 months prior
             to screening and baseline

          -  Demonstrated at least 80% compliance with the eDiary.

        Exclusion Criteria:

          -  Older than 50 years of age at migraine onset

          -  History of cluster headache or hemiplegic migraine headache

          -  Unable to differentiate migraine from other headache

          -  No therapeutic response with > 2 medication categories for prophylactic treatment of
             migraine after an adequate therapeutic trial

          -  Used a prohibited medication, device, or procedure within 2 months prior to the start
             of the baseline phase or during the baseline phase

          -  Concomitant use of 2 or more medications with possible migraine prophylactic effects
             within 2 months prior to the start of the baseline phase or during the baseline phase.
             If only 1 prophylactic medication is used, the dose must be stable within 2 months
             prior to the start of the baseline phase and throughout the study
Clinical trial NCT02459080 (phase 3, status: completed)
Conditions: chronic obstructive pulmonary disease (copd)
ICD codes: G91.1, I42.1, N11.1, J05.0, G47.33, J44.9, N13.8
Drugs: td-4208, placebo
SMILES: CN(CCN1CCC(CC1)OC(=O)NC1=CC=CC=C1C1=CC=CC=C1)C(=O)C1=CC=C(CN2CCC(CC2)C(N)=O)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Subject is a male or female subject 40 years of age or older

        Exclusion Criteria:

          -  Females who are pregnant, lactating, breast-feeding or planning to become pregnant
             during the study
Clinical trial NCT02460978 (phase 3, status: completed)
Conditions: type 1 diabetes mellitus
ICD codes: E10.65, E10.9, E10.21, E10.36, E10.41, E10.42, E10.44
Drugs: dapagliflozin
SMILES: CN(C)C(=N)NC(N)=N
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of Type 1 Diabetes mellitus (T1DM)

          -  Central laboratory C-peptide < 0.7 ng/ml (0.23 nmol/L)

          -  Insulin use for at least 12 months per patient reported or medical records

          -  Method of insulin administration (MDI or CSII) must have been unchanged for at least 3
             months prior to screening

          -  Subjects must be on a total insulin dose of ≥ 0.3 U/kg/day for at least 3 months prior
             to screening

          -  If on MDI insulin administration, subject must be on ≥ 3x injections per day

          -  Screening Visit: Central laboratory HbA1c ≥ 7.7% and ≤ 11.0%

          -  Body mass index (BMI) ≥ 18.5 kg/m2

        Exclusion Criteria:

          -  History of Type 2 Diabetes mellitus (T2DM) or maturity onset diabetes of the young
             (MODY), pancreatic surgery, or chronic pancreatitis that could result in decreased
             beta cell capacity

          -  Taking any non-insulin antihyperglicemic agent within 1 month prior to screening

          -  Taking GLP-1 receptor agonist within 2 months prior to screening for once weekly
             administration and within 1 month prior to screening for once or twice daily
             administration

          -  Taking metformin and/or thiazolidinediones within 2 months prior to screening

          -  History of diabetes ketoacidosis requiring medical intervention within 1 month prior
             to screening

          -  History of hospital admission for glycemic control (either hyperglycemia or
             hypoglycemia) within 1 month prior to screening

          -  Frequent episodes of severe hypoglycemia (more than one episode requiring medical
             assistance, emergency care), and/or glucagon therapy administered by a third-party
             individual within 1 month prior to screening

          -  History of Addison's disease
Clinical trial NCT02460991 (phase 3, status: terminated)
Conditions: hepatocellular carcinoma, hepatoma, liver cell carcinoma
ICD codes: C22.0, C4A.9, C7B.1, C4A.0, C4A.31, C4A.51, C4A.8, C22.0
Drugs: sorafenib
SMILES: CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1
Reason stopped: 
    slow enrollment
  
Eligibility criteria:

        Inclusion Criteria:

          1. Written Informed Consent

          2. ≥18 years of age

          3. Diagnosis of HCC

          4. Locally advanced HCC

          5. Preserved liver function

          6. Eastern Cooperative Oncology Group 0 or 1

        Exclusion Criteria:

          1. Presence of extra-hepatic spread of disease.

          2. Macrovascular invasion of lobar portal vein branches or main portal vein.

          3. Candidate for surgical resection, transplantation, or local ablation.

          4. Prior intra-arterial embolization, chemotherapy or systemic therapy for HCC.

          5. Any contraindication for TACE.

          6. Platelet count <50,000/mm3 or international normalized ratio >1.5.

          7. Previous treatment with anthracycline antibiotics (e.g. Doxorubicin) or sorafenib.

          8. Unstable coronary artery disease or recent myocardial infarct (i.e. within 1 year).

          9. Known ejection fraction < 50%.

         10. Current infections requiring antibiotic therapy.

         11. Suffering from a known bleeding disorder.

         12. Renal insufficiency (serum creatinine > 2 mg/dL).

         13. Aspartate aminotransferase and/or alanine transaminase >5 times upper limit of normal.

         14. Presence of advanced liver disease.

         15. Any contraindication for doxorubicin administration:

         16. Any co-morbid condition or social situation, which has a high likelihood of causing
             poor compliance with the study protocol or jeopardizes the patient's safety.

         17. Patient has another primary tumor, with the exception of conventional basal cell
             carcinoma, superficial bladder cancer, melanoma in situ, or treated prostate cancer
             currently without biochemical or radiographic evidence of active disease

         18. Participation in a clinical trial of an investigational device or drug within 4 weeks
             of study entry.

         19. Pregnant or breast-feeding patients.
Clinical trial NCT02462070 (phase 3, status: completed)
Conditions: plaque psoriasis
ICD codes: L40.0, L40.4, L40.8, L40.9, L40.1, L40.50
Drugs: idp-118 lotion, idp-118 vehicle lotion
SMILES: [H][C@@]12C[C@H](C)[C@](O)(C(=O)CCl)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C, [H][C@@]12C[C@H](C)[C@](O)(C(=O)CCl)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C
Eligibility criteria:

        Key Inclusion Criteria:

          -  Male or female, of any race, at least 18 years of age (inclusive).

          -  Freely provides both verbal and written informed consent.

          -  Has an area of plaque psoriasis appropriate for topical treatment that covers a BSA of
             at least 3%, but no more than 12%. The face, scalp, palms, soles, axillae and
             intertriginous areas are to be excluded in this calculation.

          -  Is willing and able to avoid prolonged exposure of the treatment area to ultraviolet
             radiation (natural and artificial) for the duration of the study.

          -  Has a clinical diagnosis of psoriasis at the Baseline visit with an IGA score of 3 or
             4. (The face, scalp, palms, soles, axillae and intertriginous areas are to be excluded
             in this assessment).

        Key Exclusion Criteria:

          -  Has spontaneously improving or rapidly deteriorating plaque psoriasis or pustular
             psoriasis, as determined by the investigator.

          -  Presents with psoriasis that was treated with prescription medication and failed to
             respond to treatment, even partially or temporarily, as determined by the
             investigator.

          -  Presents with any concurrent skin condition that could interfere with the evaluation
             of the treatment areas, as determined by the investigator.

          -  Is pregnant, nursing an infant, or planning a pregnancy during the study period.

          -  Has received treatment with any investigational drug or device within 60 days or 5
             drug half lives (whichever is longer) prior to the Baseline visit, or is concurrently
             participating in another clinical study with an investigational drug or device.
Clinical trial NCT02462122 (phase 3, status: completed)
Conditions: plaque psoriasis
ICD codes: L40.0, L40.4, L40.8, L40.9, L40.1, L40.50
Drugs: idp-118 lotion, idp-118 vehicle lotion
SMILES: [H][C@@]12C[C@H](C)[C@](O)(C(=O)CCl)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C, [H][C@@]12C[C@H](C)[C@](O)(C(=O)CCl)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C
Eligibility criteria:

        Key Inclusion Criteria:

          -  Male or female, of any race, at least 18 years of age (inclusive).

          -  Freely provides both verbal and written informed consent.

          -  Has an area of plaque psoriasis appropriate for topical treatment that covers a BSA of
             at least 3%, but no more than 12%. The face, scalp, palms, soles, axillae and
             intertriginous areas are to be excluded in this calculation.

          -  Is willing and able to avoid prolonged exposure of the treatment area to ultraviolet
             radiation (natural and artificial) for the duration of the study.

          -  Has a clinical diagnosis of psoriasis at the Baseline visit with an IGA score of 3 or
             4. (The face, scalp, palms, soles, axillae and intertriginous areas are to be excluded
             in this assessment).

        Key Exclusion Criteria:

          -  Has spontaneously improving or rapidly deteriorating plaque psoriasis or pustular
             psoriasis, as determined by the investigator.

          -  Presents with psoriasis that was treated with prescription medication and failed to
             respond to treatment, even partially or temporarily, as determined by the
             investigator.

          -  Presents with any concurrent skin condition that could interfere with the evaluation
             of the treatment areas, as determined by the investigator.

          -  Is pregnant, nursing an infant, or planning a pregnancy during the study period.

          -  Has received treatment with any investigational drug or device within 60 days or 5
             drug half lives (whichever is longer) prior to the Baseline visit, or is concurrently
             participating in another clinical study with an investigational drug or device.
Clinical trial NCT02462486 (phase 3, status: completed)
Conditions: macular degeneration
ICD codes: H35.30, H35.353, H35.351, H35.352, H35.359, H35.3130, H35.3230
Drugs: abicipar pegol, ranibizumab
SMILES: CN\C(NCCSCC1=CC=C(CN(C)C)O1)=C/[N+]([O-])=O
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of age-related macular degeneration in at least 1 eye

          -  Best corrected visual acuity of 20/40 to 20/320 in the study eye

          -  Best corrected visual acuity of 20/200 or better in the non-study eye

        Exclusion Criteria:

          -  History of vitrectomy, macular surgery, or glaucoma surgery in the study eye

          -  Cataract or refractive surgery in the study eye within the last 3 months